1024585-61-2

Upstream product

• 2305-87-5 4-phenylpyrimidin-2-amine 
• 7745-93-9 2-bromo-4-nitrotoluene 
• 1131-80-2 (E)-3-(N,N-dimethylamino)-1-phenyl-2-propen-1-one 
• 98-86-2 acetophenone 
• 1201-93-0 1-phenyl-3-dimethylaminoprop-2-enone 
• 99-99-0 1-methyl-4-nitrobenzene 

Downstream Products

• 782450-12-8 6-methyl-N-(4-phenylpyrimidin-2-yl)benzene-1,3-diamine 
• 1346617-92-2 N-(5-azido-2-methylphenyl)-4-phenylpyrimidin-2-amine 
• 1346617-87-5 N-[2-methyl-5-(4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-1,2,3-triazol-1-yl)phenyl]-4-phenylpyrimidin-2-amine 
• 1346617-88-6 methyl 1-[4-methyl-3-(4-phenylpyrimidin-2-ylamino)phenyl]-1H-1,2,3-triazole-4-carboxylate 
• 1346617-89-7 N-[2-methyl-5-{4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl}-phenyl]-4-phenylpyrimidin-2-amine 
• 1346617-90-0 N-[2-methyl-5-(4-phenyl-1H-1,2,3-triazol-1-yl)phenyl]-4-phenyl-pyrimidin-2-amine 
• 1346617-91-1 N-[2-methyl-5-(4-(2,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)phenyl]-4-phenylpyrimidin-2-amine 

Relevant academic research and scientific papers

N-[2-methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a Scaffold for the synthesis of inhibitors of Bcr-Abl

N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine derivatives were synthesized and evaluated invitro for their potential use as inhibitors of Bcr-Abl. The design is based on the bioisosterism between the 1,2,3-triazole ring and the amide group. The synthesis involves a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) as the key step, with the exclusive production of anti-(1,4)-triazole derivatives. One of the compounds obtained shows general activity similar to that of imatinib; in particular, it was observed to be more effective in decreasing the fundamental function of cdc25A phosphatases in the K-562 cell line. Willing and Abl inhibitors! N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine derivatives were synthesized by a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) as a key step, with anti-(1,4)-triazole derivatives as the exclusive products. One of these compounds shows general activity similar to that of imatinib, and in particular, it is more effective in decreasing the fundamental function of cdc25A phosphatases in the K-562 cell line.

A facile total synthesis of imatinib base and its analogues

Imatinib and its analogues were successfully synthesized by an improved method in 19.5-46.2% total yield of six main steps. Pyrimidinyl amine was prepared by the reaction of enaminone and guanidine nitrate without the use of a toxic cyanamide. N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl) pyrimidin-2-amine as a key intermediate for the synthesis of imatinib was prepared by coppercatalyzed iV-arylation of heteroarylamme in 82% yield. The copper salts were used instead of the expensive palladium compounds in this C-N bond-forming reaction. The intermediate nitro compound was reduced by a N2H 4.H2O/FeCl3/C system using water as a solvent in good yield.